PainRelief.com Interview with: Dr Ayşe Nur Özdag Acarli Ermenek State Hospital, Karaman, Turkey
PainRelief.com: What is the background for this study?
Response: Headache is the most common neurological problem in children and adolescents. Various factors can contribute to headache such as school, sleep, physical activity, electronic devices, mental health problems and socioeconomic conditions.
For young people, the COVID-19 pandemic has had a striking change on every aspect of life such as school closure, online education from home, fewer academic pressures, more self care at home. Early studies, examined shorter-term effects of the pandemic, reported a reduction on the prevalence of headache and chronic pain in adolescents during COVID-19, which was attributed to less school-related stress. However, in my personal clinical experience, young patients suffered more frequent and severe headaches during the pandemic, especially after the first year of the pandemic. However, literature has been lacking in the long term effects of the pandemic on headache in adolescents.
PainRelief.com Interview with: Don McGeary, PhD, ABPP Vice Chair for Research, Rehab Medicine Associate Professor, Rehab and Psychiatry UT Health San Antonio
Dr. McGeary
PainRelief.com: What is the background for this study? What are the main findings?
Response: This was a randomized clinical trial funded as part of the Consortium to Alleviate PTSD. The primary aim of the study was to test the efficacy of a novel non-pharmacological intervention (called CBT for headache; CBTH) for posttraumatic headache (PTH) attributable to mild traumatic brain injury (mTBI).
PTH is the most common and disabling consequence of mild traumatic brain injury and is a large concern for military service members and veterans in the post-9/11 deployment era because of the significant increase in head injury in this population over the last 20 years. Posttraumatic headache has been recognized under various labels (including “shell shock” and “hero’s headache”) for over a century, but there are no proven, frontline treatments for PTH. PTH is unique among headache diagnoses because it is classified as a secondary headache (i.e., develops as a consequence of another medical phenomenon, mTBI) and because it is diagnosed based on the injury that led to the headache with no criteria for specific clinical characteristics. Thus, the “phenotype” of posttraumatic headache is variable with the most frequent reports describing symptoms consistent with migraine AND tension type headaches.
Unfortunately, because the underlying mechanisms of PTH differ from the primary headaches they resemble, frontline medications (abortive and prophylactic) may not have the same efficacy for PTH as they do for the primary headaches for which they are usually prescribed. To complicate things further, PTH is often acquired in the context of a traumatic experience (blast, firearms overpressure, motor vehicle accident, other traumatic injury), so PTSD is highly comorbid with these headaches and there is an evolving body of research showing that PTSD can complicate, maintain and worsen pain.
Thus, our study sought to (1) Test a novel non-pharmacological intervention tailored to PTH rehabilitation and (2) Assess the relationship between PTSD and PTH to determine if preferred treatment pathways should include PTSD treatment as well.
This resulted in a three-arm trial comparing CBTH to a gold-standard non-pharmacological treatment for PTSD and usual care in a large VA polytrauma center.
PainRelief.com Interview with: Oved Daniel MD Headache and Facial Pain Clinic Ramat-Aviv Medical Center President of the Israeli Headache Association Tel-Aviv, Israel
PainRelief.com: What is the background for this study? What are the main findings?
Response: Migraine patients experience disabling symptoms, which often left untreated or exasperated by currently available therapies, therefore, a significant unmet medical need for treating migraine pain remains.
Current external nerve stimulation devices only target one nerve and this study assessed the safety and performance of a new external nerve stimulation device that stimulates the two major nerve branches associate with pain (occipital and trigeminal) .
The Relivion MG is a non-invasive device that the patient can wear at home to treat their migraine pain and associate symptoms.
PainRelief.com Interview with: Andrew F. Russo, Ph.D. Professor, Dept. Molecular Physiology and Biophysics University of Iowa Iowa City, IA 52242
Dr. Russo
PainRelief.com: What is the background for this study?
Response: The company Schedule 1 Therapeutics approached us with an interest in testing a combination of CBD:THC in migraine. We thought the topic had tremendous public interest so we teamed up with them and won grants from the Migraine Research Foundation and from the National Institute on Drug Abuse.
PainRelief.com Interview with: Douglas P. Beall, MD, FSIR Chief of Radiology Services Clinical Radiology of Oklahoma
Dr. Bealll
PainRelief.com: What is the background for this study?
Response: Degenerative disc disease (DDD) is the leading cause of chronic low back pain and one of the world’s most common medical conditions contributing to high medical and disability costs. Healthy spinal discs act aids spine movement and distributes force which allows for spine flexibility and even distribution of the load that is placed on the spine. Each has a firm outer layer and a soft, jelly-like core. With normal aging, discs tend to become dry, thin, cracked or torn, which can cause pain and abnormal motion.
Substances called hydrogels, with biochemical similarities to the intervertebral disc designed to augment both the core and outer layer, have been used for years to help repair degenerated discs. First-generation hydrogels are placed as a soft solid, through a surgical incision, but were not simple to place and had a tendency to migrate from where they were originally placed.
For a first-in-human trial, our team conducted a prospective, single-arm feasibility study to evaluate an experimental, injectable hydrogel for safety and performance in relieving chronic low back pain caused by DDD. We used a second-generation hydrogel (Hydrafil™) developed by ReGelTec, Inc.. Unlike earlier hydrogels, it can be temporarily modified into a liquid and injected rather than placed through a small incision. In 2020, this product received FDA’s breakthrough device designation, allowing expedited review based on promising early evidence.
We recruited 20 patients, aged 22 to 69, who each described their pain as four or higher on a zero to 10 scale. None had found more than mild relief from non-surgical management, which includes rest, analgesics, physical therapy, and back braces. Patients were sedated for the procedure, and the gel was heated to become a thick liquid. Guided by fluoroscopic imaging, an interventional radiologist used a 17-gauge needle to inject the gel directly into the affected disc(s). The gel filled in cracks and tears and adhered to the disc’s core and outer layer.
PainRelief.com Interview with: Kun Zhang PhD Senior Service Fellow and Health Scientist Opioid Overdose Prevention Health Systems Team Division of Unintentional Injury Prevention Centers for Disease Control and Prevention
Dr. Zhang
PainRelief.com: What is the background for this study? are the main findings?
Response: When taken together by patients, opioids and benzodiazepines can result in synergistic respiratory depression which elevates overdose risk; however, these two medications have been commonly co-prescribed in the U.S.
Since 2016 there has been efforts to address the concurrent use of these two drugs, for example the 2016 FDA Boxed Warning and the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain.
Our study aimed at tracking and analyzing recent trends in concurrent use of these two medications using national level data.
PainRelief.com Interview with: Mwidimi Ndosi PhD MSc BSc PGCert (Clin Ed) FHEA RN Sarah Bennet and Beth Jones Associate Professor in Rheumatology Nursing University of the West of England, Bristol Honorary Researcher University Hospitals Bristol and Weston NHS Trust
Dr.Ndosi
PainRelief.com: What is the background for this study? What are the main findings?
Response:Patient education is seen as an essential part of managing long-term conditions like inflammatory arthritis. Chronic inflammatory arthritis includes rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. We define patient education as a planned interactive learning process designed to support and enable people to manage their life with a disease and optimise their health and wellbeing.[1]
There are variations across Europe in the way patient education is delivered to people with inflammatory arthritis. In 2015, an international group of professionals and patients with inflammatory arthritis developed evidence-based recommendations for patient education [1]. This initiative was supported by the European Alliance of Associations for Rheumatology (EULAR), an organisation representing people with arthritis, health professionals in rheumatology and scientific societies of rheumatology in Europe.
In this study, we wanted to find out whether the recommendations were acceptable to patients and healthcare professionals. We also needed to know what helped people to follow these recommendations and what were barriers to putting them into practice. We surveyed health professionals in 20 countries in Europe, and 3 in Asia (India, Hong Kong and Japan) [2]
PainRelief.com Interview with: Kao–PingChua, MD, PhD Department of Pediatrics Susan B. Meister Child Health Evaluation and Research Center University of Michigan Medical School Department of Health Management and Policy University of Michigan School of Public Health, Ann Arbor
PainRelief.com: What is the background for this study?
Response: Opioid prescriptions written by dentists and surgeons are almost always written for the immediate relief of acute pain after procedures. However, current federal and state laws allow these prescriptions to be dispensed well after the time that they are written. When this occurs, that could be a potential sign that the prescription was used in a time frame or for a reason other than intended by the prescriber, both of which are forms of prescription opioid misuse.
PainRelief.com Interview with: David (Dedi) Meiri PhD Principal Investigato Laboratory of Cancer Biology and Cannabinoid Research Technion Israel Institute of Technology
PainRelief.com: What is the background for this study?
Response: We encountered numerous cancer patients that asked us whether medical cannabis treatment can benefit their health, however, while there is a lot of anecdotal evidence regarding the effectiveness of medical cannabis for pain, not much was known regarding its effectiveness in particular for the treatment of cancer-related pain; and there were no validated clinical studies. This motivated us to conduct an organized and thorough study that can serve patients and government ministries alike.
This study, which was conducted by Dr. Joshua Aviram as part of his postdoctoral fellowship, is the first to assess the possible benefits of medical cannabis for cancer-related pain in oncology patients, gathering information from right before they started the treatment and with repeated follow-ups for an extended period of time. Over a span of six months, we investigated the effectiveness and safety of medical cannabis treatment based on sound real-world evidence.
PainRelief.com Interview with: Janni Leung, PhD National Health and Medical Research Council Emerging Leadership Fellow National Centre for Youth Substance Use Research (NCYSUR) The University of Queensland
PainRelief.com: What is the background for this study?
Response: It is important to know the prevalence and source of medical cannabis use because non-prescribed use may put individuals at risk.
The information on PainRelief.com is provided for educational purposes only, and is in no way intended to diagnose, endorese, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website. None of the content on PainRelief.com is warranted by the editors or owners of PainRelief.com or Eminent Domains Inc.
Thank you for visiting PainRelief.com
Senior Editor, Marie Benz MD.
For more information, or for advertising options please email: [email protected] or [email protected]
